Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsUnitedHealthcare Juxtapid Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentUnitedHealthcarePolicy N/A

    Juxtapid (lomitapide) Coverage Criteria

    Customize your policy alerts

    Sign up for all UnitedHealthcare policy alerts

    Know when UnitedHealthcare releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs UnitedHealthcare prior authorization and medical-necessity coverage for Juxtapid in members with homozygous familial hypercholesterolemia. It establishes initial authorization, reauthorization, step-therapy, documentation, prescriber, combination-therapy, and authorization-duration requirements.

    Policy Summary
    PayerUnitedHealthcare
    PolicyJuxtapid (lomitapide) Coverage Criteria
    Policy CodePolicy N/A
    Change TypePolicy update
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation confirming HoFH, required lipid-lowering therapy, applicable step therapy or current Juxtapid use, and qualified specialist prescribing.
    SourceLink
    POLICY UPDATE CHANGES

    Step-therapy criteria were updated based on the updated FDA labeling for Repatha.

    Current Juxtapid therapy may bypass the step-therapy criteria when claims history or medical records document ongoing therapy.

    The requirement prohibiting combination use with PCSK9 inhibitors was removed.

    12 monthsInitial and reauthorization approval period
    Age 2+Patients included in the labeled indication

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    >400 mg/dL
    Untreated LDL-C threshold in one HoFH diagnostic pathway
    4 genesGenes identified for qualifying pathogenic variants
    2 agentsRequired failed or contraindicated step agents for patients age 10 years or older

    Coverage Criteria

    Initial Therapy

    Covered when ALL of the following criteria are met:

    ALL of the following

    • ONE of the following HoFH diagnosis pathways

      • Submission of medical records (e.g., chart notes and laboratory values) confirming genetic confirmation of bi-allelic pathogenic/likely pathogenic variants on different chromosomes in the LDLR, APOB, PCSK9, or LDLRAP1 genes, or at least two such variants at different loci.
      • ALL of the following

        • Untreated LDL-C is greater than 400 mg/dL.
        • ONE of the following

          • Xanthoma before 10 years of age.
          • Evidence of familial hypercholesterolemia in at least one parent.
    • Patient is on a low-fat diet.
    • Patient is receiving other lipid-lowering therapy (e.g., statin, ezetimibe, or LDL apheresis).
    • ONE of the following prescribing and therapy pathways

      • ALL of the following

        • Patient is greater than or equal to 10 years of age.
        • History of intolerance, failure, or contraindication to Repatha (evolocumab).
        • History of intolerance, failure, or contraindication to Evkeeza (evinacumab).
      • ALL of the following

        • Patient is less than 10 years of age.
        • History of failure, contraindication, or intolerance to Evkeeza (evinacumab).
      • ALL of the following

    • Juxtapid is not used in combination with Evkeeza (evinacumab-dgnb).

    Continuation Therapy

    Covered when ALL of the following criteria are met:

    ALL of the following

    • Patient is on a low-fat diet.
    • Patient continues to receive other lipid-lowering therapy (e.g., statin or LDL apheresis).
    • Documentation demonstrates a positive clinical response to therapy from the pre-treatment baseline.
    • ONE of the following prescribers

      • Cardiologist.
      • Endocrinologist.

    Juxtapid must not be used in combination with Evkeeza (evinacumab-dgnb).

    Juxtapid is not medically necessary for hypercholesterolemia in patients who do not have homozygous familial hypercholesterolemia (HoFH), because its safety and efficacy have not been established in that population.

    Clinical Thresholds

    Untreated LDL-C
    Untreated LDL-C threshold>400 mg/dL
    Required diagnostic pathwayClinical confirmation of HoFH
    Additional clinical evidenceXanthoma before age 10 or evidence of familial hypercholesterolemia in at least one parent

    Authorization and Documentation Requirements

    Prior Authorization

    Initial Authorization Required

    Prior authorization is required for initial Juxtapid authorization. Approval requires meeting all applicable initial-authorization criteria, including HoFH diagnosis, low-fat diet, other lipid-lowering therapy, qualified prescriber, an applicable treatment-history pathway, and no concurrent Evkeeza use.

    • Initial authorization is issued for 12 months.
    Prior Authorization

    Reauthorization Required Every 12 Months

    Reauthorization is required every 12 months. Continued approval requires documentation that the patient remains on a low-fat diet, continues other lipid-lowering therapy, has a positive clinical response from pretreatment baseline, is treated by a qualified prescriber, and is not using Juxtapid with Evkeeza.

    • Each reauthorization period is 12 months.

    Clinical Background

    Juxtapid (lomitapide) is a microsomal triglyceride transfer protein inhibitor indicated as an adjunct to a low-fat diet, exercise, and other LDL-C-lowering therapies to reduce LDL-C in adult and pediatric patients aged 2 years and older with homozygous familial hypercholesterolemia (HoFH).

    HoFH Diagnostic Definition

    Genetic HoFH confirmation
    Variant typeBi-allelic pathogenic or likely pathogenic variants on different chromosomes, or at least two such variants at different loci
    Qualifying genesLDLR, APOB, PCSK9, or LDLRAP1
    DocumentationMedical records such as chart notes and laboratory values confirming the genetic findings

    Juxtapid Initial Authorization

    Juxtapid Initial Authorization

    Initial authorization is approved when all applicable criteria are met:

    Juxtapid initial authorization

    • HoFH diagnosis

      • Genetic confirmation: Medical records confirm bi-allelic pathogenic or likely pathogenic variants on different chromosomes in LDLR, APOB, PCSK9, or LDLRAP1, or at least two such variants at different loci.
      • Clinical confirmation

        • Untreated LDL-C is greater than 400 mg/dL.>400 mg/dL untreated LDL-C
        • ONE of

    Juxtapid Continuation Therapy

    Juxtapid Continuation Therapy

    Reauthorization is approved when all of the following are met:

    Juxtapid continuation requirements

    • The patient remains on a low-fat diet.
    • The patient continues to receive other lipid-lowering therapy, such as a statin or LDL apheresis.
    • Documentation shows a positive clinical response to therapy compared with the pretreatment baseline.
    • Juxtapid is prescribed by a cardiologist, endocrinologist, or lipid specialist.
    • Juxtapid is not used in combination with Evkeeza (evinacumab-dgnb).

    Required Prior Therapy

    Patient ageStep-therapy requirement
    Age 10 years or olderHistory of intolerance, failure, or contraindication to both Repatha (evolocumab) and Evkeeza (evinacumab).
    Patient ageStep-therapy requirement
    Younger than age 10History of failure, contraindication, or intolerance to Evkeeza (evinacumab).
    Policy Summary
    PayerUnitedHealthcare
    PolicyJuxtapid (lomitapide) Coverage Criteria
    Policy CodePolicy N/A
    Change TypePolicy update
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation confirming HoFH, required lipid-lowering therapy, applicable step therapy or current Juxtapid use, and qualified specialist prescribing.
    SourceLink
    On This Page
    Coverage CriteriaClinical ThresholdsAuthorization and Documentation RequirementsClinical BackgroundHoFH Diagnostic DefinitionJuxtapid Initial AuthorizationJuxtapid Continuation TherapyRequired Prior Therapy
    • Patient is currently on Juxtapid therapy, as documented by claims history or submission of medical records.

      Document the date and duration of therapy.

    • Patient has not received a manufacturer-supplied sample at no cost in the prescriber office or any form of assistance from the Chiesi-sponsored Juxtapid copay program (e.g., a sample card redeemable through a pharmacy for a free supply) as a means to establish current Juxtapid use.

      Patients established on therapy through a manufacturer-supplied sample or Chiesi-sponsored Juxtapid copay assistance must meet the initial authorization criteria as if new to therapy.

    Lipid specialist.
  1. Juxtapid is not used in combination with Evkeeza (evinacumab-dgnb).
  2. Step Therapy

    Age 10 or Older: Repatha and Evkeeza History

    For patients age 10 years or older, document a history of intolerance, failure, or contraindication to both Repatha (evolocumab) and Evkeeza (evinacumab) to satisfy the applicable initial-therapy pathway.

    • Patient must be greater than or equal to 10 years of age.
    • Both Repatha and Evkeeza treatment history requirements apply.
    Step Therapy

    Younger Than Age 10: Evkeeza History

    For patients younger than age 10, document a history of failure, contraindication, or intolerance to Evkeeza (evinacumab) to satisfy the applicable initial-therapy pathway.

    • Patient must be less than 10 years of age.
    • Evkeeza treatment-history documentation is required.

    Unsupported block type: step_therapy

    Documentation Required

    Document HoFH Diagnosis

    Document homozygous familial hypercholesterolemia (HoFH) using qualifying genetic or clinical evidence. Genetic evidence must show qualifying bi-allelic pathogenic or likely pathogenic variants; alternatively, clinical evidence must include untreated LDL-C greater than 400 mg/dL plus xanthoma before age 10 or familial hypercholesterolemia in at least one parent.

    • Genetic evidence may involve LDLR, APOB, PCSK9, or LDLRAP1 variants on different chromosomes, or at least two such variants at different loci.
    • Submit medical records such as chart notes and laboratory values.
    Documentation Required

    Document Current Juxtapid Use

    Submit claims history or medical records supporting that the patient is currently receiving Juxtapid and documenting the date and duration of therapy. Also document that current use was not established through a free manufacturer sample or Chiesi-sponsored Juxtapid copay assistance.

    • Patients established through those assistance mechanisms must satisfy initial authorization criteria as new to therapy.
    Documentation Required

    Document Continuation and Response

    For reauthorization, document ongoing use of a low-fat diet and other lipid-lowering therapy, together with a positive clinical response from the pretreatment baseline. The response documentation should support continued benefit from Juxtapid therapy.

    • Examples of other lipid-lowering therapy include a statin or LDL apheresis.
    • Reauthorization is required every 12 months.
    Documentation Required

    Document Qualified Prescriber

    The prescription must be written by a qualified specialist. Identify the treating prescriber as a cardiologist, endocrinologist, or lipid specialist for initial authorization and reauthorization.

    • Include the prescriber's specialty in the submitted documentation.

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Step Therapy

    Step Therapy Not Satisfied

    The applicable step-therapy pathway must be satisfied before initial Juxtapid approval. Patients age 10 years or older must have a history of intolerance, failure, or contraindication to both Repatha and Evkeeza; patients younger than age 10 must have a history of failure, contraindication, or intolerance to Evkeeza, unless they qualify through the current Juxtapid user pathway.

    • A current-user request must include claims or medical-record support for ongoing therapy and must not rely on prohibited manufacturer samples or copay assistance to establish current use.
    • Failure to meet the applicable pathway may result in denial.
  3. Xanthoma was present before 10 years of age.
  4. There is evidence of familial hypercholesterolemia in at least one parent.
  5. The patient is on a low-fat diet and receiving other lipid-lowering therapy, such as a statin, ezetimibe, or LDL apheresis.
  6. Qualified prescriber: Juxtapid is prescribed by a cardiologist, endocrinologist, or lipid specialist.
  7. ONE applicable access pathway

    • Age 10 years or older step therapy

      • The patient is at least 10 years of age.Age ≥10 years
      • The patient has a history of intolerance, failure, or contraindication to Repatha (evolocumab).
      • The patient has a history of intolerance, failure, or contraindication to Evkeeza (evinacumab).
    • Younger than age 10 step therapy

      • The patient is younger than 10 years of age.Age <10 years
      • The patient has a history of failure, contraindication, or intolerance to Evkeeza (evinacumab).
    • Current Juxtapid therapy

      • The patient is currently receiving Juxtapid, documented by claims history or medical records showing the date and duration of therapy.
      • The therapy was not established through a manufacturer-supplied free sample or any assistance from the Chiesi-sponsored Juxtapid copay program.
  8. Combination restriction: Juxtapid is not used in combination with Evkeeza (evinacumab-dgnb).